Neodymium:YAG Lasers: An FDA Report

Walter J. Stark; David Worthen; Jack T. Holladay; George Murray

doi:10.1016/S0161-6420(85)34051-4

Neodymium:YAG Lasers: An FDA Report

Walter J. Stark, David Worthen, Jack T. Holladay, George Murray

Research output: Contribution to journal › Article › peer-review

127 Scopus citations

Abstract

Analysis of data from four neodymium:YAG laser manufacturers submitted to the Food and Drug Administration (FDA) on over 17,000 cases indicate the procedure is safe and effective for cutting opaque posterior lens capsules. A successful opening in the pupillary membrane was achieved in 98% of the cases, and vision improved in 84% of the cases. Clinically significant risks include: a rise in intraocular pressure two to four hours after treatment, damage to the intraocular lens, and rupture of the anterior hyaloid face.

Original language	English (US)
Pages (from-to)	209-212
Number of pages	4
Journal	Ophthalmology
Volume	92
Issue number	2
DOIs	https://doi.org/10.1016/S0161-6420(85)34051-4
State	Published - 1985
Externally published	Yes

Keywords

FDA
cystoid macular edema
glaucoma
intraocular lens
neodymium:YAG laser
posterior capsule opacification

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0161-6420(85)34051-4

Cite this

@article{030615368ac84ac0810bf6ba08049124,

title = "Neodymium:YAG Lasers: An FDA Report",

abstract = "Analysis of data from four neodymium:YAG laser manufacturers submitted to the Food and Drug Administration (FDA) on over 17,000 cases indicate the procedure is safe and effective for cutting opaque posterior lens capsules. A successful opening in the pupillary membrane was achieved in 98% of the cases, and vision improved in 84% of the cases. Clinically significant risks include: a rise in intraocular pressure two to four hours after treatment, damage to the intraocular lens, and rupture of the anterior hyaloid face.",

keywords = "FDA, cystoid macular edema, glaucoma, intraocular lens, neodymium:YAG laser, posterior capsule opacification",

author = "Stark, {Walter J.} and David Worthen and Holladay, {Jack T.} and George Murray",

year = "1985",

doi = "10.1016/S0161-6420(85)34051-4",

language = "English (US)",

volume = "92",

pages = "209--212",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Neodymium:YAG Lasers

T2 - An FDA Report

AU - Stark, Walter J.

AU - Worthen, David

AU - Holladay, Jack T.

AU - Murray, George

PY - 1985

Y1 - 1985

N2 - Analysis of data from four neodymium:YAG laser manufacturers submitted to the Food and Drug Administration (FDA) on over 17,000 cases indicate the procedure is safe and effective for cutting opaque posterior lens capsules. A successful opening in the pupillary membrane was achieved in 98% of the cases, and vision improved in 84% of the cases. Clinically significant risks include: a rise in intraocular pressure two to four hours after treatment, damage to the intraocular lens, and rupture of the anterior hyaloid face.

AB - Analysis of data from four neodymium:YAG laser manufacturers submitted to the Food and Drug Administration (FDA) on over 17,000 cases indicate the procedure is safe and effective for cutting opaque posterior lens capsules. A successful opening in the pupillary membrane was achieved in 98% of the cases, and vision improved in 84% of the cases. Clinically significant risks include: a rise in intraocular pressure two to four hours after treatment, damage to the intraocular lens, and rupture of the anterior hyaloid face.

KW - FDA

KW - cystoid macular edema

KW - glaucoma

KW - intraocular lens

KW - neodymium:YAG laser

KW - posterior capsule opacification

UR - http://www.scopus.com/inward/record.url?scp=0021909894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021909894&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(85)34051-4

DO - 10.1016/S0161-6420(85)34051-4

M3 - Article

C2 - 3982799

AN - SCOPUS:0021909894

SN - 0161-6420

VL - 92

SP - 209

EP - 212

JO - Ophthalmology

JF - Ophthalmology

IS - 2

ER -

Neodymium:YAG Lasers: An FDA Report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this